RARE Insider Sanders Corazon (Corsee) Sells $50K of Stock

On June 15, 2026, Sanders Corazon sold 2,000 shares of Ultragenyx Pharmaceutical Inc. (NasdaqGS: RARE) at an average price of $25.05 each. The transaction was valued at $50,100 and was not part of a pre-arranged trading plan.

Insider Buying and Selling at Ultragenyx Pharmaceutical Inc.

In addition to Sanders Corazon's sale, several other insiders have been active. On the same day, Karah Herdman Parschauer, Executive Vice President and Chief Legal Officer, sold 1,899 shares at $24.62 under a planned sale. Earlier in the month, on June 1, Chief Financial Officer Howard Horn sold 4,653 shares at $23.77, also under a planned sale. Shehnaaz Suliman sold 5,740 shares at $25.12 on May 18 and bought 14,058 shares on May 14.

Other Institutional Activity in Ultragenyx Pharmaceutical

Institutional investors have also been adjusting their positions in Ultragenyx. BlackRock, Inc. increased its holdings by 668,044 shares, resulting in a total of 7,299,598 shares valued at approximately $152.9 million. Vanguard Portfolio Management LLC added 5,385,992 shares, bringing its total to the same number, valued at about $112.8 million. Meanwhile, State Street Corp boosted its stake by 718,395 shares, ending with 5,021,441 shares worth roughly $105.2 million. AQR Capital Management LLC significantly increased its position by 3,217,527 shares to 4,578,024 shares, valued at $95.9 million.

Ultragenyx Pharmaceutical Inc. Stock Up 74.9%

Shares of Ultragenyx Pharmaceutical Inc. traded near $24.35. The company has a market cap of around $2.4 billion and a forward P/E ratio of 25.23. It has a beta of 0.378, indicating lower volatility compared to the market. The stock's 52-week range is between $18.29 and $42.37, with a 50-day moving average of $24.06 and a 200-day moving average of $27.12.

Recent Earnings

Ultragenyx Pharmaceutical reported revenue of $670 million, with a slight decline of 2.2% in revenue growth. The company posted a net margin of -90.9%, reflecting ongoing challenges in profitability. Earnings per share were negative at -$6.10. The next earnings report is expected on August 4, 2026.

Analysts Set New Price Targets

Several analysts have maintained their ratings on Ultragenyx Pharmaceutical. On May 21, 2026, Cantor Fitzgerald maintained a 'buy' rating with a target price of $96. Guggenheim also maintained a 'buy' rating with a target of $43. Wells Fargo and Barclays both echoed this sentiment, setting targets at $47 and $43 respectively. The consensus among analysts is a strong buy, with an average target price of $52.05 based on 19 opinions.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company based in Novato, California. It focuses on developing treatments for rare and ultra-rare genetic diseases across various regions including North America, Latin America, Europe, and Asia-Pacific. The company's product lineup includes Crysvita, Mepsevii, Dojolvi, and Evkeeza, targeting different rare conditions. Founded in 2010, Ultragenyx is led by CEO Dr. Emil D. Kakkis and employs over 1,370 people.

Bottom Line

Insider transactions, like Sanders Corazon's recent sale, are closely watched by investors as potential indicators of company sentiment. Ultragenyx Pharmaceutical's stock remains under scrutiny with a strong buy consensus from analysts, despite its recent financial performance challenges. As always, it's important to remember that insider transactions and 13F filings are backward-looking and may not reflect current positions.